Key result
Heparin pre-treatment in STEMI patients was associated with a reduced risk of intracoronary thrombus and total vessel occlusion prior to PCI.
Why the study?
Does pre-treatment with unfractionated heparin reduce the risk of intracoronary thrombus and total vessel occlusion in patients with STEMI prior to percutaneous coronary intervention?
Observational (n=7,144)
Yes
Does pre-treatment with unfractionated heparin reduce the risk of intracoronary thrombus and total vessel occlusion in patients with STEMI prior to percutaneous coronary intervention?
Pre-treatment with unfractionated heparin in STEMI patients is associated with reduced intracoronary thrombus burden and total vessel occlusion prior to PCI without increasing bleeding risk.
Answers are grounded in this paper and cite their sources.
Heparin pre-treatment may reduce thrombus in STEMI; leaves open whether it improves outcomes in randomized trials.
BACKGROUND:: Pre-treatment with unfractionated heparin is common in ST-segment elevation myocardial infarction (STEMI) protocols, but the effect on intracoronary thrombus burden is unknown. We studied the effect of heparin pre-treatment on intracoronary thrombus burden and Thrombolysis in Myocardial Infarction (TIMI) flow prior to percutaneous coronary intervention in patients with STEMI. METHODS:: The Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial angiographically assessed intracoronary thrombus burden and TIMI flow, prior to percutaneous coronary intervention, in patients with STEMI. In this observational sub-study, patients pre-treated with heparin were compared with patients not pre-treated with heparin. Primary end points were a visible intracoronary thrombus and total vessel occlusion prior to percutaneous coronary intervention. Secondary end points were in-hospital bleeding, in-hospital stroke and 30-day all-cause mortality. RESULTS:: Heparin pre-treatment was administered in 2898 out of 7144 patients (41.0%). Patients pre-treated with heparin less often presented with an intracoronary thrombus (61.3% vs. 66.0%, p<0.001) and total vessel occlusion (62.9% vs. 71.6%, p<0.001). After adjustments, heparin pre-treatment was independently associated with a reduced risk of intracoronary thrombus (odds ratio (OR) 0.73, 95% confidence interval (CI)=0.65-0.83) and total vessel occlusion (OR 0.64, 95% CI=0.56-0.73), prior to percutaneous coronary intervention. There were no significant differences in secondary end points of in-hospital bleeding (OR 0.84, 95% CI=0.55-1.27), in-hospital stroke (OR 1.17, 95% CI=0.48-2.82) or 30-day all-cause mortality (hazard ratio 0.88, 95% CI=0.60-1.30). CONCLUSIONS:: Heparin pre-treatment was independently associated with a lower risk of intracoronary thrombus and total vessel occlusion before percutaneous coronary intervention in patients with STEMI, without evident safety concerns, in this large multi-centre observational study.
No takes yet. Share an insight, caveat, or question.
Karlsson et al. (2017) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=7,144). Heparin pre-treatment vs. No heparin pre-treatment was evaluated on Visible intracoronary thrombus prior to percutaneous coronary intervention (OR 0.73, 95% CI 0.65-0.83, p=<0.001). Heparin pre-treatment in STEMI patients was associated with a reduced risk of intracoronary thrombus and total vessel occlusion prior to PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: